<DOC>
	<DOCNO>NCT01040910</DOCNO>
	<brief_summary>Background : The marijuana plant Cannabis use century medicinal treatment many disorder still subject medical research public debate . Cannabinoids purport alleviate variety neurological condition MS-related symptom include spasticity , pain , tremor bladder dysfunction . Other neurological condition like chronic intractable pain , dystonic movement disorder Tourette 's Syndrome report alleviated cannabis use . Cannabis use treat anorexia AIDS cancer patient . In gastroenterology cannabis use treat symptom diseases include anorexia , emesis , abdominal pain , gastroenteritis , diarrhoea , intestinal inflammation diabetic gastroparesis . Cannabinoids also profound anti inflammatory effect , mainly CB2 receptor . Cell mediate immunity may impair chronic marijuana user . And potent anti-inflammatory effect cannabis observe rat . Studying functional role endocannabinoid system immune modulation reveals major immune event involve endocannabinoid system . Cannabinoids shift balance pro-inflammatory cytokine anti-inflammatory cytokine towards T-helper cell type 2 profile ( Th2 phenotype ) , suppress cell-mediated immunity whereas humoral immunity may enhance . They therefore use various inflammatory condition include rheumatoid arthritis asthma . In mouse model colitis cannabinoids find ameliorate inflammation many anecdotal report effect cannabis inflammatory bowel disease . However , methodical report effect cannabis inflammatory bowel disease . The aim propose study examine double blind placebo control fashion effect smoke cannabis disease activity patient IBD .</brief_summary>
	<brief_title>Cannabis Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<criteria>1 . Patients diagnosis IBD least 3 month recruitment eligible study . 2 . Patients active disease resistant either 5 ASA , steroids immunomodulators , receive drug due adverse reaction offer possibility smoke cannabis dose two cigarette day contain either regular cannabis pre treat cannabis placebo . 3 . Disease activity index either CDAI 200 Crohn 's disease Mayo score 3 UC . 4 . Age 20 . 1 . Patients know mental disorder 2 . Patients deem high risk abuse addiction study drug . 3 . Pregnant woman 4 . Patients sensitive ingredient study medication . 5 . Patients unable give inform consent . 6 . Patients may need surgery near future .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>cannabis</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>IBD</keyword>
</DOC>